SODIUM CHLORIDE | N018803 | HOSPIRA INC
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Citizen Petition from Medefil Inc FDA-2018-P-3176 Medefil Inc. submitted this citizen petition on August 15, 2018, requesting that the FDA assign a Therapeutic Equivalence Evaluation Code of "AP" in the Orange Book for its NDA 202832, Sodium Chloride Injection, USP, 0.9%, to designate the product as therapeutically equivalent to Hospira's NDA 01880 | Other | 2018-08-16 | Denied | Medefil Inc |
APP Pharmaceuticals - Citizen Petition FDA-2009-P-0104 The provided document contains FDA electronic Orange Book listings for sodium chloride 0.9% injectable solution in plastic containers approved under three NDAs held by Hospira, but does not include the actual citizen petition text stating who filed it or what specific action was requested. | Other | 2009-02-26 | Withdrawn | — |
Source: Regulations.gov. FDA citizen petitions matched by application number.
Highest NADAC/Unit
$0.0915
per ml
Lowest NADAC/Unit
$0.0915
per ml
Brand NDCs
0
Generic NDCs
2
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 00409488810SODIUM CHLORIDE 0.9% VIAL | $0.0915 | ML | Generic | — | 2026-10-21 |
| 00409488812SODIUM CHLORIDE 0.9% VIAL | $0.0915 | ML | Generic | — | 2026-10-21 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.